Janssen-Cilag GmbH

Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article Chronische Entzündungserkrankungen in Deutschland: Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz (2023) Leipe J, Schmelz R, Riemekasten G, Thaçi D, Henes J, Schäkel K, Pinter A, et al. Journal article Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab (2022) Gerdes S, Asadullah K, Hoffmann M, Korge B, Mortazawi D, Wegner S, Personke Y, et al. Journal article Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article Psoriasis in routine clinical care: Complete skin clearance rates with guselkumab increase through week 52-Results from the real-life PERSIST study (2021) Hoffmann M, Sticherling M, Korge B, Mortazawi D, Personke Y, Gomez M, Wegner S, Gerdes S Conference contribution Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma (2021) Straka C, Salwender H, Knop S, Vogel M, Muller J, Metzner B, Langer C, et al. Journal article EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar C, Shawi M, et al. Conference contribution Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial (2021) Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, et al. Journal article Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy (2021) Tully KH, Jütte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, Breyer J, et al. Journal article Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS) (2020) Thaci D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, et al. Journal article